Cargando…
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953385/ https://www.ncbi.nlm.nih.gov/pubmed/36830969 http://dx.doi.org/10.3390/biomedicines11020433 |
_version_ | 1784893865299279872 |
---|---|
author | Becciolini, Andrea Parisi, Simone Del Medico, Patrizia Farina, Antonella Visalli, Elisa Molica Colella, Aldo Biagio Lumetti, Federica Caccavale, Rosalba Scolieri, Palma Andracco, Romina Girelli, Francesco Bravi, Elena Colina, Matteo Volpe, Alessandro Ianniello, Aurora Ditto, Maria Chiara Nucera, Valeria Franchina, Veronica Platè, Ilaria Donato, Eleonora Di Amato, Giorgio Salvarani, Carlo Bernardi, Simone Lucchini, Gianluca De Lucia, Francesco Molica Colella, Francesco Santilli, Daniele Mansueto, Natalia Ferrero, Giulio Marchetta, Antonio Arrigoni, Eugenio Foti, Rosario Sandri, Gilda Bruzzese, Vincenzo Paroli, Marino Fusaro, Enrico Ariani, Alarico |
author_facet | Becciolini, Andrea Parisi, Simone Del Medico, Patrizia Farina, Antonella Visalli, Elisa Molica Colella, Aldo Biagio Lumetti, Federica Caccavale, Rosalba Scolieri, Palma Andracco, Romina Girelli, Francesco Bravi, Elena Colina, Matteo Volpe, Alessandro Ianniello, Aurora Ditto, Maria Chiara Nucera, Valeria Franchina, Veronica Platè, Ilaria Donato, Eleonora Di Amato, Giorgio Salvarani, Carlo Bernardi, Simone Lucchini, Gianluca De Lucia, Francesco Molica Colella, Francesco Santilli, Daniele Mansueto, Natalia Ferrero, Giulio Marchetta, Antonio Arrigoni, Eugenio Foti, Rosario Sandri, Gilda Bruzzese, Vincenzo Paroli, Marino Fusaro, Enrico Ariani, Alarico |
author_sort | Becciolini, Andrea |
collection | PubMed |
description | Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA. |
format | Online Article Text |
id | pubmed-9953385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99533852023-02-25 Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study Becciolini, Andrea Parisi, Simone Del Medico, Patrizia Farina, Antonella Visalli, Elisa Molica Colella, Aldo Biagio Lumetti, Federica Caccavale, Rosalba Scolieri, Palma Andracco, Romina Girelli, Francesco Bravi, Elena Colina, Matteo Volpe, Alessandro Ianniello, Aurora Ditto, Maria Chiara Nucera, Valeria Franchina, Veronica Platè, Ilaria Donato, Eleonora Di Amato, Giorgio Salvarani, Carlo Bernardi, Simone Lucchini, Gianluca De Lucia, Francesco Molica Colella, Francesco Santilli, Daniele Mansueto, Natalia Ferrero, Giulio Marchetta, Antonio Arrigoni, Eugenio Foti, Rosario Sandri, Gilda Bruzzese, Vincenzo Paroli, Marino Fusaro, Enrico Ariani, Alarico Biomedicines Article Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA. MDPI 2023-02-02 /pmc/articles/PMC9953385/ /pubmed/36830969 http://dx.doi.org/10.3390/biomedicines11020433 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Becciolini, Andrea Parisi, Simone Del Medico, Patrizia Farina, Antonella Visalli, Elisa Molica Colella, Aldo Biagio Lumetti, Federica Caccavale, Rosalba Scolieri, Palma Andracco, Romina Girelli, Francesco Bravi, Elena Colina, Matteo Volpe, Alessandro Ianniello, Aurora Ditto, Maria Chiara Nucera, Valeria Franchina, Veronica Platè, Ilaria Donato, Eleonora Di Amato, Giorgio Salvarani, Carlo Bernardi, Simone Lucchini, Gianluca De Lucia, Francesco Molica Colella, Francesco Santilli, Daniele Mansueto, Natalia Ferrero, Giulio Marchetta, Antonio Arrigoni, Eugenio Foti, Rosario Sandri, Gilda Bruzzese, Vincenzo Paroli, Marino Fusaro, Enrico Ariani, Alarico Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
title | Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
title_full | Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
title_fullStr | Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
title_full_unstemmed | Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
title_short | Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study |
title_sort | predictors of dapsa response in psoriatic arthritis patients treated with apremilast in a retrospective observational multi-centric study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953385/ https://www.ncbi.nlm.nih.gov/pubmed/36830969 http://dx.doi.org/10.3390/biomedicines11020433 |
work_keys_str_mv | AT beccioliniandrea predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT parisisimone predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT delmedicopatrizia predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT farinaantonella predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT visallielisa predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT molicacolellaaldobiagio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT lumettifederica predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT caccavalerosalba predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT scolieripalma predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT andraccoromina predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT girellifrancesco predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT bravielena predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT colinamatteo predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT volpealessandro predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT iannielloaurora predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT dittomariachiara predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT nuceravaleria predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT franchinaveronica predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT plateilaria predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT donatoeleonoradi predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT amatogiorgio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT salvaranicarlo predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT bernardisimone predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT lucchinigianluca predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT deluciafrancesco predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT molicacolellafrancesco predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT santillidaniele predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT mansuetonatalia predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT ferrerogiulio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT marchettaantonio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT arrigonieugenio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT fotirosario predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT sandrigilda predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT bruzzesevincenzo predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT parolimarino predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT fusaroenrico predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy AT arianialarico predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy |